Our methods of clinical examination, diagnosis, and treatment have been described previously.1 For the purposes of this case series, we recorded the following data prior to initial therapy: age, race, sex, medical history (hypertension, diabetes mellitus, hypercholesterolemia, dysplastic nevus syndrome, skin melanoma), family history (choroidal or skin melanoma), ocular symptoms, examination findings (visual acuity, anterior segment details, intraocular pressure), and tumor findings (quadrant of tumor epicenter, number of clock hours surrounding the optic disc, percentage of overhang of the optic disc by the tumor, distance of tumor margin to foveola and optic disc in millimeters, largest basal diameter and thickness in millimeters, tumor configuration, color, extraocular extension, retinal invasion, subretinal fluid, orange pigment, optic disc swelling, and retinal vascular congestion). The following plaque radiation particulars were recorded: radionuclide isotope (iodine 125 [125I], ruthenium 106, cobalt 60 [60Co], iridium 192), plaque size in millimeters, plaque shape (round, notched, postage stamp), custom seed distribution (full or posterior, according to the basal dimensions and elevation of the tumor and oriented perpendicular to the optic nerve and foveola to minimize radiation exposure to these sensitive structures), time of radiation exposure (hours), and radiation dose (centigrays) and rate (centigrays per hour) to the tumor apex, tumor base, optic disc, foveola, and lens. Currently, 8000 cGy is the preferred radiation dose to the tumor apex. Adjunctive treatment details with TTT,14 argon laser photocoagulation (ALPC), or krypton laser photocoagulation were ascertained. Cumulative follow-up data included treatment complications (any degree of nonproliferative and proliferative radiation retinopathy, maculopathy, papillopathy, radiation cataract, neovascular glaucoma, vitreous hemorrhage, scleral necrosis, venous or arterial occlusion), long-term visual acuity, loss of vision of more than 5 Snellen visual acuity lines, enucleation, tumor recurrence (Figure 3), systemic metastases, and death.